Adagene Inc.: Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates
Adagene (Nasdaq: ADAG) reported six months ended June 30, 2026 results and clinical updates on muzastotug (ADG126). Cash and equivalents were $127.9 million, extending runway into late 2028. Phase 1b/2 data in MSS CRC with pembrolizumab showed ORR 13% to 31% and median PFS 4.8 to 6.7 months, with Phase 2 results expected in 1H 2027.
How this was made
The 30-second read
Why it matters
The company’s update combines (1) interim efficacy and safety detail by muzastotug dose schedule, (2) trial progression with a randomized Phase 2 readout targeted for 1H 2027, and (3) a cash runway extension into late 2028 following an April 2026 public offering.
Market read
Traders may reprice ADAG’s probability-weighted clinical success and financing risk based on the reported ORR/PFS by dose, the randomized Phase 2 timeline, and the stated cash runway into late 2028.
What to watch
The article emphasizes safety and ORR/PFS, but does not provide statistical significance, durability beyond medians, or full adverse-event detail across all cohorts, which can temper enthusiasm.
Background
Adagene is a clinical-stage biotech developing muzastotug (ADG126), a masked anti-CTLA-4 SAFEbody, across MSS CRC and HCC in combination with PD-1 and other agents.
Ticker impact
Adagene reported six-month 2026 results and detailed muzastotug Phase 1b/2 efficacy, including ORR/PFS by dose and a randomized Phase 2 readout expected in 1H 2027.
Near-term sentiment likely positive on the combination of new clinical efficacy detail and runway extension, with volatility around the 1H 2027 Phase 2 readout.
The article provides multiple concrete efficacy endpoints by dose regimen, ongoing trial timelines, and a stated cash runway extension from an April 2026 offering, all of which can move biotech risk perception.
Market effects
Reinforces investor appetite for next-gen CTLA-4 approaches and combination immunotherapy backbones in MSS CRC and HCC.
Limited direct regional spillover; primarily US-listed biotech sentiment.
Potential read-through to global oncology trial design and partnership activity, including collaboration with Sanofi and use of pembrolizumab/IO backbones.
Counterpoint
Interim Phase 1b/2 results are based on small cohorts and multiple dose schedules, so the market may discount the magnitude until randomized Phase 2 confirms dose regimen selection.
Key entities
- companyAdagene Inc.
Nasdaq-listed clinical-stage biotech reporting six-month 2026 financial results and muzastotug clinical updates.
- drug_programmuzastotug (ADG126)
Masked anti-CTLA-4 SAFEbody being tested in MSS CRC and HCC combinations.
- therapypembrolizumab (KEYTRUDA)
Anti-PD-1 agent used in combination regimens described in the Phase 1b/2 and randomized Phase 2 designs.
- partnerSanofi
Clinical collaboration partner referenced for a global Phase 1/2 basket trial combining muzastotug with an investigational IO agent.
- partnerMerck (MSD outside US/Canada)
Referenced as the source of the anti-PD-1 therapy used with muzastotug in MSS CRC.
